Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
ROLLNICK, S., HEATHER, N., GOLD, R., & HALL, W. (1992) · British Journal of Addiction · doi:10.1111/j.1360-0443.1992.tb02720.x · Cited by 818
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Ruan, W. J., & Pickering, R. P. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.4.361 · Cited by 644
Heyser, C. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00130-9 · Cited by 176
Mason, B. J. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.009 · Cited by 75
Self-citation
Cited by
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
Self-citationJonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 712
Helping Patients Who Drink Too Much: A Clinician's Guide: (495492006-001)
US Department of Health and Human Services; National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism (2005) · PsycEXTRA Dataset · doi:10.1037/e495492006-001 · Cited by 589
Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451
“W HILE PHARMACOtherapy for alcohol dependence is limited, several drugs have received Food and Drug Administration approval.(1,2) Meta-analyses of many single-site and multisite studies of the opioid antagonist medication naltrexone hydrochloride have suggested that the effect size for response over placebo is in the…”
BackgroundAcamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Self-citationLingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“In addition, failure of the two US trials to find acamprosate effective would fit with this hypothesis, since participants were less severely dependent (COMBINE, Anton et al., 2006; Mason et al., 2006) (Ib).”
BackgroundRösner, S., Leucht, S., Lehert, P., & Soyka, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107078308 · Cited by 300
Self-citationGarbutt, J. C., Kampov‐Polevoy, A. B., Gallop, R., Kalka‐Juhl, L., & Flannery, B. A. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01273.x · Cited by 294
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis
McPheeters, M., O’Connor, E. A., Riley, S., Kennedy, S. M., Voisin, C., Kuznacic, K., Coffey, C. P., Edlund, M. D., Bobashev, G., & Jonas, D. E. (2023) · JAMA · doi:10.1001/jama.2023.19761 · Cited by 285
Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework
Koob, G. F., & Colrain, I. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0446-0 · Cited by 276
Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264
Glutamatergic targets for new alcohol medications
Holmes, A., Spanagel, R., & Krystal, J. H. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3226-2 · Cited by 197
“Magnetic resonance imaging studies have found that glutamate levels in the hippocampus and anterior cingulate cortex are increased during early withdrawal, but return to normal within 3 days post-withdrawal (Hermann et al. 2012; Mason et al. 2006b; Mon et al. 2012).”
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
Development of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Self-citationTargeting glutamate uptake to treat alcohol use disorders
Rao, P. S. S., Bell, R. L., Engleman, E. A., & Sari, Y. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00144 · Cited by 136
“Moreover, the effects of ethanol consumption onNMDA- andmGlu-R as well as Homer (a glutamatergic receptor scaffolding protein) subunit expression in the extended amygdala and Acb core are also influenced by the length of ethanolwithdrawal (Obara et al., 2009).”
BackgroundAssessment and treatment of insomnia in adult patients with alcohol use disorders
Brower, K. J. (2015) · Alcohol · doi:10.1016/j.alcohol.2014.12.003 · Cited by 134
21st century neurobehavioral theories of decision making in addiction: Review and evaluation
Bickel, W. K., Mellis, A. M., Snider, S. E., Athamneh, L. N., Stein, J. S., & Pope, D. A. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.09.009 · Cited by 134
“Some antagonists of this system have reduced alcohol consumption in a double-blind, placebo-control trial (Mason et al., 2006).”
BackgroundExisting and future drugs for the treatment of the dark side of addiction
Koob, G. F., & Mason, B. J. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103143 · Cited by 121
Self-citationPharmacotherapy for alcohol dependence: status of current treatments
Franck, J., & Jayaram-Lindström, N. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.005 · Cited by 107
Medications for substance use disorders
Douaihy, A. B., Kelly, T. M., & Sullivan, C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.759031 · Cited by 93
Tolliver, B. K., DeSantis, S. M., Brown, D. G., Prisciandaro, J. J., & Brady, K. T. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00973.x · Cited by 74
“However, a number of adequately powered negative trials of acamprosate have been reported (34, 43, 44), and even large meta-analyses that support the efficacy of acamprosate have reported modest effect sizes (40, 45, 46).”
Garbutt, J. C., Kampov-Polevoy, A. B., Pedersen, C., Stansbury, M., Jordan, R., Willing, L., & Gallop, R. J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01055-w · Cited by 68
Acamprosate: a review of its use in alcohol dependence
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0423-9 · Cited by 65
“[34] ACA 2 g/day (253) 56 (&6 months) ACA 3 g/day (82) 61”
BackgroundPerney, P., Lehert, P., & Mason, B. J. (2012) · Alcohol and Alcoholism · doi:10.1093/alcalc/agr160 · Cited by 48
Self-citation
Metadata
- Authors
- MASON, B., GOODMAN, A., CHABAC, S., & LEHERT, P.
- Venue
- Journal of Psychiatric Research
- Publisher
- Elsevier BV
- Published
- 2006-08
- Volume
- 40
- Issue
- 5
- Pages
- 383-393
- ISSN
- 0022-3956 (ISSN-L)
- OpenAlex
- W2023831713
- Cited by
- 212
- References
- 6
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.